Cancer Cell Research (Online ISSN: 2161-2609)
Current Issue
Vol.7 No.27
Article: Second generation sequencing was performed to detect the gene mutation of PIk3CA in gynecological tumors and its relationship with the prognosis of patients
by Yuanli Guo, Junfeng Liu,Chen Shan
Cancer Cell Research 2020 7(27) 714-719; published online 15 July 2020
Abstract:
To investigate the gene mutation of PIk3CA in gynecological
tumors and analyze the relationship between PIk3CA and
median survival time. Our study included gynecologic tumor
patients 110 cases ((40 cases of cervical cancer, 40 cases
of endometrial carcinoma, 30 cases of ovarian cancer) from
January 2011 1 to August 2019, the First Affiliated Hospital
of Sun Yat-sen University and Sun Yat-sen University
Affiliated Hospital of Department of Gynaecology. Paraffin
tumor samples from patients with postoperative, cut out the
white piece, extract DNA, using the second generation
sequencing of high-throughput sequencing platform, access to
genetic testing results, the Kaplan-Meier survival curve
analysis state of PIk3CA gene and the relationship between
gynecological malignant tumor patients' overall survival
time. In 110 patients with gynecological tumor, 61 cases
(55.45%) patients had PIk3CA gene mutations, consensus don't
9745 variants, including 7215 single nucleotide mutation and
2530 missing or insertion mutation, type of PIk3CA mutations
in patients with cervical cancer and ovarian cancer gene
amplification, highly PIk3CA mutations in endometrial
carcinoma was 36.67% (11/30), cervical cancer was 57.5%
(23/40), ovarian cancer was 67.5% (27/40), compared with
tissue adjacent to carcinoma (P < 0.05). The follow-up
period was June 1, 2019, and a total of 98 patients were
followed up. In cervical cancer and ovarian cancer, the poor
prognosis of patients with PIk3CA gene mutation was
significantly reduced in the non-mutation group (P=0.001),
but no correlation was found between PIk3CA gene mutation
and the survival time of patients in endometrial cancer.
PIk3CA gene is highly extended in gynecological tumors,
especially in ovarian cancer and cervical cancer, and is
closely related to the poor prognosis of patients, which is
great value for guiding clinical prognosis and guiding
precise treatment.
Open Access Download (free) PDF
Article: Research progress of hematological indicators related to the prognosis of Small-cell lung cancer that can be easily ignored in clinical work
by Haocheng Wang, Ya Dong, Dongfeng Shan, Xue Yang, Qi Qi, Linwei Zhang, Zhuang Yu
Cancer Cell Research 2020 7(27) 720-728; published online 25 August 2020
Abstract:
Lung cancer has the highest incidence and mortality in the
world. Small-cell lung cancer (SCLC) accounts for about 15%
of the total lung cancer, which belongs to neuroendocrine
tumor, and among the patients, there are about 1/3 belong to
the Limited Stage (LS). Chemotherapy combined with
radiotherapy is the standard treatment for patients with
LS-SCLC patients. However, SCLC is extremely aggressive and
prone to early distant metastasis, and most of the patients
are already in the Extensive Stage (ES) when they start
seeking treatment. The prognosis of ES-SCLC patients is very
poor, and its treatment has made little progress in recent
decades. Therefore, sensitive and accurate indicators are
needed to evaluate the prognosis of patients before starting
treatment. Many studies have used hematology indexes at the
initial diagnosis to predict the prognosis of SCLC patients,
it involves liver function, routine blood coagulation and
routine blood tests, including lactate dehydrogenase,
fibrinogen, D-dimer, the ratio of neutrophils to
lymphocytes(NLR), the ratio of platelets to
lymphocytes(PLR), etc., which can play a role in the
clinical work to indicate the treatment node.
Open Access Download (free) PDF
Article: Research progress on the prevention of colorectal cancer with Phytic Acid
by Jingjing Wang, Genquan Jin, Xiubo Jiang
Cancer Cell Research 2020 7(27) 729-735; published online 25 August 2020
Abstract:
Phytic acid is an inositol ester containing six molecules of
phosphoric acid, which is ubiquitous in plant seeds. It has
various biological effects such as chelating,
anti-oxidation, regulating immunity, anti-tumor, reducing
inflammation, and inducing autophagy. A large number of
animal and in vitro experiments have confirmed that phytic
acid is a broad-spectrum anti-tumor substance that has
effects on different cell and tissue systems. The number of
people diagnosed with colorectal cancer each year is second
only to lung cancer and breast cancer, ranking third in the
world. It is a common gastrointestinal malignant tumor in my
country. Metastasis is a key feature of malignant tumors,
and it is also a difficult point in the treatment of cancer.
Most treatments for colorectal cancer have side effects, and
phytic acid has no obvious toxicity to normal cells. It can
inhibit the metastasis of colorectal cancer, but its
specific mechanism is not clear. If the mechanism of action
can be clarified, it will provide a new target for the
prevention and treatment of colorectal cancer. In this
article, we reviewed the research progress of phytic acid
and the mechanism of action of colorectal cancer metastasis.
Open Access Download (free) PDF
Article: Advances in anticancer activity of natural products from fungi
by Chen Liu, Yajie Shao, Feilong Deng, Fang Yuan, Yuchen Chen, Shiyi Wen,
Jingyuan Zhang, Wen Zhao, Zekun He, Jinyi Yan, Xiangyi Cui, Xinyue Sun,
Changwu Yue, Yuhong Lv
Cancer Cell Research 2020 7(27) 736-743; published online 25 September 2020
Abstract:
The species and structure of active natural products from
fungi are rich and diverse, which can affect many
physiological and biochemical processes and are an important
source of clinical antitumor drugs. In this paper, the
origin, activity and mechanism of antifungal natural
products are reviewed, and their future applications are
prospected.
Open Access Download (free) PDF
Article: Application of ixazomib monotherapy and combination therapy in patients with multiple myeloma
by Shimeng Wang, Ying Wu, Wang Wei
Cancer Cell Research 2020 7(27) 744-748; published online 25 September 2020
Abstract:
In the past few decades, the survival rate of patients with
multiple myeloma has improved significantly. This
improvement is mainly due to the development of proteasome
inhibitors and immunomodulatory drugs, which are the
cornerstone of the treatment of multiple myeloma. Ixazomib
is a selective and reversible proteasome inhibitor. It can
be used as a single agent or combined with other
immunomodulators to treat multiple myeloma. This article
mainly reviews the effectiveness and safety evaluation of
ixazomib monotherapy and its combination therapy in patients
with multiple myeloma prospected.
Open Access Download (free) PDF